For example, between 1976 and 2008, African Americans were victims of 329,825 homicides. Although there is a widespread perception that war is the most dangerous form of armed violence in the world, the average person living in a conflict-affected country had a risk of dying violently in the conflict of about 2.0 per 100,000 population between 2004 and 2007. This can be compared to the average world homicide rate of 7.6 per 100,000 people. This illustration highlights the value of accounting for all forms of armed violence rather than an exclusive focus on conflict related violence. Certainly, there are huge variations in the risk of dying from armed conflict at the national and subnational level, and the risk of dying violently in a conflict in specific countries remains extremely high. In Iraq, for example, the direct conflict death rate for 2004–07 was 65 per 100,000 people per year and, in Somalia, 24 per 100,000 people. This rate even reached peaks of 91 per 100,000 in Iraq in 2006 and 74 per 100,000 in Somalia in 2007. History
Scientific evidence for warfare has come from settled, sedentary communities. Some scholars argue humans may have a predisposition for violence (chimpanzees, also great apes, have been known to kill members of competing groups for resources like food), placing the origins of organized violence prior to modern settled societies.
Eluxadoline, sold under the brand names Viberzi and Truberzi, is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use in the United States in 2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis. Contraindications
This drug is contraindicated in case of having:

Blockage of the gallbladder or a sphincter of Oddi problem
Problems with excessive alcohol use
Pancreatitis
Liver problems
Chronic or severe constipation

Adverse effects
Common adverse effects are constipation and nausea, but rates of discontinuation due to constipation were low for both eluxadoline and placebo. Rare adverse effects: fatigue, bronchitis, viral gastroenteritis. Rare serious adverse effects include pancreatitis with a general incidence of 0.3% - higher incidence with 100 mg dose (0.3%) than with 75 mg dose (0.2%). The risk is even greater in those who do not have a gall bladder and the medication is not recommended in this group.In March 2017, the U.S. Food and Drug Administration issued a safety alert for eluxadoline concerning an increased risk of serious pancreatitis in patients without a gallbladder. An FDA review found that in such patients, spasm of the sphincter of Oddi may lead to severe pancreatitis. The FDA reported that in some cases symptoms have occurred with just one or two doses at the recommended dosage for patients without a gallbladder (75 mg). Of two deaths associated with eluxadoline reported up to February 2017, both occurred in patients without a gallbladder.